Mouse LILRB4/CD85k/ILT3 Protein

产品信息(Product Info)
表达区间及表达系统(Source)

Recombinant Mouse LILRB4/CD85k/ILT3 Protein is expressed from HEK293 with His tag at the C-Terminus. It contains Gly24-Lys238.[Accession | Q64281-1]

分子量大小(Molecular Weight)

The protein has a predicted MW of 25.1 kDa. Due to glycosylation, the protein migrates to 30-45 kDa based on Tris-Bis PAGE result.

内毒素(Endotoxin)

Less than 1EU per μg by the LAL method.

纯度(Purity)

> 95% as determined by Tris-Bis PAGE
> 95% as determined by HPLC

制剂(Formulation)

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

重构方法(Reconstitution)

Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.

存储(Storage)

-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3-6 months after reconstitution.
2-8°C for 2-7 days after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

产品数据(Assay Data)
Tris-Bis PAGE

Mouse LILRB4 on Tris-Bis PAGE under reduced conditions. The purity is greater than 95%.

SEC-HPLC

The purity of Mouse LILRB4 is greater than 95% as determined by SEC-HPLC.

SPR Data

Mouse LILRB4, His Tag immobilized on CM5 Chip can bind Mouse APOE, His Tag with an affinity constant of 5.08 nM as determined in SPR assay (Biacore T200).

背景(Background)

LILRB4,also known as CD85k and LIR-5, ILT3,  is an approximately 60 kDa transmembrane glycoprotein that negatively regulates immune cell activation. Mature human ILT3 consists of a 238 amino acid (aa) extracellular domain with two Ig-like domains, a 21 aa transmembrane segment, and a 168 aa cytoplasmic domain with 3 immunoreceptor tyrosine-based inhibitory motifs (ITIM).LILRB4 is receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles.

分子别名(Synonyms)

HM18; ILT3; ILT-3; LILRB4; LIR5; CD85K

文献(References)

(1)Samuel J , Heyu C , Mi D , et al. A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML[J]. Molecular Therapy, 2018:S1525001618303721-.

Note: HPLC results always come from liquid protein, due to absorption peak interference of trehalose in lypholized powder.